Phase 3 trials of thalidomide containing maintenance after ASCT
| Study . | Group . | PFS . | OS . | Comments . |
|---|---|---|---|---|
| Spencer et al48 | Control | 23 | 75 | At 3 years |
| Thalidomide Prednisone | 42 | 86 | ||
| Barlogie et al3 | Control | 20 | 44 | At 8 years |
| Thalidomide | 45 | 57 | ||
| Attal et al49 | Control | 36 | 77 | At 3 years after randomization for EFS, 4 years after diagnosis for OS |
| Thalidomide | 52 | 87 |
| Study . | Group . | PFS . | OS . | Comments . |
|---|---|---|---|---|
| Spencer et al48 | Control | 23 | 75 | At 3 years |
| Thalidomide Prednisone | 42 | 86 | ||
| Barlogie et al3 | Control | 20 | 44 | At 8 years |
| Thalidomide | 45 | 57 | ||
| Attal et al49 | Control | 36 | 77 | At 3 years after randomization for EFS, 4 years after diagnosis for OS |
| Thalidomide | 52 | 87 |
EFS indicates event-free survival, and OS, overall survival.